• 1
    Mutani R, Cantello R, Gianelli M., Rational basis for the development of new antiepileptic drugs. Epilepsy Res 1991;suppl 3:238.
  • 2
    Krogsgaard-Larsen P, Falch E, Larsson OM, Schousboe A., GABA uptake inhibitors: relevance to antiepileptic drug research. Epilepsy Res 1987;1:7793.
  • 3
    Pfeiffer M, Draguhn A, Meierkord H, Heinemann U., Effects of gamma aminobutyric acid (GABA) agonists and GABA uptake inhibitors on pharmacosensitive and pharmacoresistant epilepti-form activity in vitro. Br J Pharmacol 1996;119:56977.
  • 4
    Andersen KE, Braestrup C, Gronwald FC, The synthesis of novel GABA uptake inhibitors. 1. Elucidation of the structure-activity studies leading to the choice of (R)-1-[4,4-bis(3-methyl-2-thienyl)-3-butenyl]-3-piperidinecarboxylic acid (tiagabine) as an anticonvulsant drug candidate. J Med Chem 1993;36:171625.
  • 5
    Richens A, Chadwick DW, Duncan JS, Adjunctive treatment of partial seizures with tiagabine: a placebo-controlled trial. Epilepsy Res 1995;21:3742.
  • 6
    Schachter SC, Tiagabine monotherapy in the treatment of partial epilepsy. Epilepsia 1995;36(suppl 6):S26.
  • 7
    Borden LA, Murali Dhar TG, Smith KE, Weishank RL, Branchek TA, Genchowski C., Tiagabine, SKF 89976A, CI-966, and NNC-711 are selective for the cloned GABA transporter GAT-1. Eur J Pharmacol 1994;269:21924.
  • 8
    Jursky F, Nelson N., Developmental expression of GABA transporters GAT1 and GAT4 suggests involvement in brain maturation. J Neurochem 1996;67:85767.
  • 9
    Yan X-X, Cariaga WA, Ribak CE, Immunoreactivity for GABA plasma membrane transporter, GAT-1, in the developing rat cerebral cortex: transient presence in the somata of neocortical and hippocampal neurons. Dev Brain Res 1997;99:119.
  • 10
    Nielsen EB, Suzdak PD, Andersen KE, Knutsen LJS, Sonnewald U, Braestrup C., Characterization of tiagabine (NO-328), a new potent and selective GABA uptake inhibitor. Eur J Pharmacol 1991;196:25766.
  • 11
    Suzdak PD, Jansen JA, A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor. Epilepsia 1995;36:61226.
  • 12
    Brodie MJ, Tiagabine pharmacology in profile. Epilepsia 1995;36(suppl 6):S79.
  • 13
    Dalby NO, Nielsen EB, Comparison of the preclinical anticonvulsant profiles of tiagabine, lamotrigin, gabapentin and vigabatrin. Epilepsy Res 1997;28:6372.
  • 14
    Walton NY, Gunawan S, Treiman DM, Treatment of experimental status epilepticus with the GABA uptake inhibitor, tiagabine. Epilepsy Res 1994;19:23744.
  • 15
    Halonen T, Nissinen J, Jansen JA, Pitkanen A., Tiagabine prevents seizures, neuronal damage and memory impairment in experimental status epilepticus. Eur J Pharmacol 1996;299:6981.
  • 16
    Coleman MH, Yamaguchi S, Rogawski MA, Protection against dendrotoxin-induced clonic seizures in mice by anticonvulsant drugs. Brain Res 1992;575:13842.
  • 17
    Yamaguchi S, Rogawski MA, Effects of anticonvulsant drugs on 4-aminopyridine-induced seizures in mice. Epilepsy Res 1992;11:916.
  • 18
    Coenen AML, Blezer EHM, van Luijtelaar ELJM, Effects of the GABA-uptake inhibitor tiagabine on electroencephalogram, spiKewave discharges and behaviour of rats. Epilepsy Res 1995;21:8994.
  • 19
    Hosford DA, Wang Y., Utility of the lethargic (1h/1h) mouse model of absence seizures in predicting the effects of lamotrigine, vigabatrin, tiagabine, gabapentin, and topiramate against human absence seizures. Epilepsia 1997;38:40814.
  • 20
    Ben-Menachem E., International experience with tiagabine add-on therapy. Epilepsia 1995;36(suppl 6):S1421.
  • 21
    Dulac O, Bulteau C, Pedersen S, et al. The challenges of epilepsy in children. Epilepsia 1997;38(suppl 2):S14.
  • 22
    Mareš P, Marešová D, Schickerová R., Effect of antiepileptic drugs on metrazol convulsions during ontogenesis in the rat. Physiol Bohemoslov 1981;30:11321.
  • 23
    Mareš P., Ontogeny of ethosuximide action against two seizure models in rats is different. Life Sci 1998;63:PL517.
  • 24
    Kubová H, Mareš P., Anticonvulsant effects of phenobarbital and primidone during ontogenesis in rats. Epilepsy Res 1991;10:14855.
  • 25
    Stanková L, Kožuchová A, Mareš P., Anticonvulsant effect of progabide in rats during ontogenesis. Phys Res 1997;46:4752.
  • 26
    Loscher W, Schmidt D., Which animals models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res 1988;2:14581.
  • 27
    Mareš P, Zouhar A., Do we possess adequate models of childhood epilepsies Physiol Bohemoslov 1988;37:19.
  • 28
    Velíšek L, Kubová H, Pohl M, Stanková L, Mareš P, Schickerová R., Pentylenetetrazol-induced seizures in rats: an ontogenetic study. Naunyn-Schmiedeberg's Arch Pharmacol 1992;346:58891.
  • 29
    Pohl M, Mareš P., Flunarizine influences metrazol-induced seizures in developing rats. Epilepsy Res 1987;1:3025.
  • 30
    Loiseau P., Review of controlled trials of Gabitril (tiagabine): a clinician's viewpoint. Epilepsia 1999;409(suppl 9):S149.
  • 31
    Smith SE, Parvez NS, Chapma A, Meldrum BS, The gamma-aminobutyric acid uptake inhibitor, tiagabine, is anticonvulsant in two animal models of reflex epilepsy. Eur J Pharmacol 1995;273:25965.
  • 32
    Kubová H, Haugvicová R, Mareš P., Effects of NNC 711, a GABA uptake inhibitor, on pentylenetetrazol-induced seizures in developing and adult rats. Naunyn-Schmiedeberg's Arch Pharmacol 1998;358:33441.
  • 33
    Kubová H., NNC-711: an inhibitor of GABA uptake with selective affinity to GAT-1. CNS Drug Rev 1999;5:31730.
  • 34
    Dobbing J., Undernutrition and the developing brain. In: HimwichWA, ed. Developmental neurobiology. Springfield , IL : Charles C Thomas, 1970:24161.
  • 35
    Gustavson LE, Boellner SW, Granneman GR, et al. A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures. Neurology 1997;48:10327.
  • 36
    Gustavson LE, Mengel HB, Pharmacokinetics of tiagabine, a gamma-aminobutyric acid-uptake inhibitor, in healthy subjects after single and multiple doses. Epilepsia 1995;36:60511.
  • 37
    So EL, Wolff D, Graves NM, Pharmacokinetics of tiagabine as add-on therapy in patients taking enzyme-inducing antiepilepsy drugs. Epilepsy Res 1995;22:2216.
  • 38
    Bopp BA, Gustavson LE, Rodrigues AD, Role of cytochrome P450 3A subfamily in the metabolism of [14C]tiagabine by human hepatic microsomes, Epilepsia 1995;36(suppl 3):S159.
  • 39
    Kubová H, Mareš P., Time course of the anticonvulsant action of clonazepam in the developing rats. Arch Int Pharmacodyn Ther 1989;298:1524.
  • 40
    Stanková L, Kubová H, Mareš P., Anticonvulsant action of lamotrigine during ontogenesis in rats. Epilepsy Res 1992;13:1722.
  • 41
    Kubová H, Haugvicová R, Mareš P., Anticonvulsant effect of SL 75 102 in adult and immature rats. Phys Res 1997;46:736.
  • 42
    Gray JA, Green AR, GABA-B-receptor mediated inhibition of potassium-evoked release of endogenous 5-hydroxytryptamine from mouse frontal cortex. Br J Pharmacol 1987;91:51722.
  • 43
    Kubová H, Mareš P., Anticonvulsant action of oxcarbamazepine, hydroxycarbamazepine and carbamazepine against metrazol-induced motor seizures in developing rats. Epilepsia 1993;34:18892.